{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:07:50Z","timestamp":1791976070861,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40261-025-01445-8","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T05:35:04Z","timestamp":1746250504000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-8291","authenticated-orcid":false,"given":"Yugo","family":"Chisaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokatsu","family":"Nyuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Harano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"1445_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348. https:\/\/doi.org\/10.1056\/NEJMra1001389.","journal-title":"N Engl J Med"},{"key":"1445_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7497\/j.issn.2095-3941.2015.0030","volume":"12","author":"HA Wahba","year":"2015","unstructured":"Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106\u201316. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0030.","journal-title":"Cancer Biol Med"},{"key":"1445_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000508759","volume":"15","author":"J Furlanetto","year":"2020","unstructured":"Furlanetto J, Loibl S. Optimal systemic treatment for early triple-negative breast cancer. Breast Care (Basel). 2020;15:217\u201326. https:\/\/doi.org\/10.1159\/000508759.","journal-title":"Breast Care (Basel)."},{"key":"1445_CR4","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1007\/s00330-022-08910-4","volume":"32","author":"DL Sheng","year":"2022","unstructured":"Sheng DL, Shen XG, Shi ZT, Chang C, Li JW. Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics. Eur Radiol. 2022;32:6575\u201387. https:\/\/doi.org\/10.1007\/s00330-022-08910-4.","journal-title":"Eur Radiol"},{"key":"1445_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137. https:\/\/doi.org\/10.1038\/nature14011.","journal-title":"Nature"},{"key":"1445_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5306\/wjco.v13.i3.219","volume":"13","author":"GA Valencia","year":"2022","unstructured":"Valencia GA, Rioja P, Morante Z, Ruiz R, Fuentes H, Castaneda CA, et al. Immunotherapy in triple-negative breast cancer: a literature review and new advances. World J Clin Oncol. 2022;13:219\u201336. https:\/\/doi.org\/10.5306\/wjco.v13.i3.219.","journal-title":"World J Clin Oncol."},{"key":"1445_CR7","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"key":"1445_CR8","unstructured":"U.S. Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Accessed 14 Feb 2024."},{"key":"1445_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12913-020-05445-6","volume":"20","author":"LC Phua","year":"2020","unstructured":"Phua LC, Lee SC, Ng K, Abdul Aziz MI. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020;20:581. https:\/\/doi.org\/10.1186\/s12913-020-05445-6.","journal-title":"BMC Health Serv Res"},{"key":"1445_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40261-021-01017-6","volume":"41","author":"Y Chisaki","year":"2021","unstructured":"Chisaki Y, Kuwada Y, Matsumura C, Yano Y. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for advanced PD-L1 positive triple-negative breast cancer in Japan. Clin Drug Investig. 2021;41:381\u20139. https:\/\/doi.org\/10.1007\/s40261-021-01017-6.","journal-title":"Clin Drug Investig"},{"key":"1445_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COC.0000000000000671","volume":"43","author":"X Weng","year":"2020","unstructured":"Weng X, Huang X, Li H, Lin S, Rao X, Guo X, et al. First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. 2020;43:340\u20138. https:\/\/doi.org\/10.1097\/COC.0000000000000671.","journal-title":"Am J Clin Oncol"},{"key":"1445_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.801.","journal-title":"Ann Oncol"},{"key":"1445_CR13","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer. Accessed 14 Feb 2024."},{"key":"1445_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"key":"1445_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2202809.","journal-title":"N Engl J Med"},{"key":"1445_CR16","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1002\/cam4.5757","volume":"12","author":"M Hattori","year":"2023","unstructured":"Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, et al. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: results from KEYNOTE-355. Cancer Med. 2023;12:10280\u201393. https:\/\/doi.org\/10.1002\/cam4.5757.","journal-title":"Cancer Med"},{"key":"1445_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2217\/imt-2022-0082","volume":"14","author":"M Huang","year":"2022","unstructured":"Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, et al. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy. 2022;14:1027\u201341. https:\/\/doi.org\/10.2217\/imt-2022-0082.","journal-title":"Immunotherapy"},{"key":"1445_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health. 2017;20:372\u20138. https:\/\/doi.org\/10.1016\/j.jval.2016.08.726.","journal-title":"Value Health."},{"key":"1445_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3111\/13696998.2013.784591","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. J Med Econ. 2013;16:713\u20139. https:\/\/doi.org\/10.3111\/13696998.2013.784591.","journal-title":"J Med Econ"},{"key":"1445_CR20","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23:1613\u201321. https:\/\/doi.org\/10.1016\/j.jval.2020.08.2094.","journal-title":"Value Health."},{"key":"1445_CR21","unstructured":"Team RDC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2007. http:\/\/www.R-projectorg."},{"key":"1445_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2021;21:111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"key":"1445_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322\u201338. https:\/\/doi.org\/10.1177\/0272989X9301300409.","journal-title":"Med Decis Making"},{"key":"1445_CR24","first-page":"1034","volume":"54","author":"Japan Nephrology Society","year":"2012","unstructured":"Japan Nephrology Society. Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012;54:1034\u2013191.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"1445_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788569","volume":"12","author":"Q Liu","year":"2021","unstructured":"Liu Q, Zhou Z, Luo X, Yi L, Peng L, Wan X, et al. First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: a cost-effectiveness analysis. Front Pharmacol. 2021;12: 788569. https:\/\/doi.org\/10.3389\/fphar.2021.788569.","journal-title":"Front Pharmacol"},{"key":"1445_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/jjco\/hyab071","volume":"51","author":"H Okumura","year":"2021","unstructured":"Okumura H, Inoue S, Naidoo S, Holmstrom S, Akaza H. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naive metastatic castration-resistant prostate cancer in Japan. Jpn J Clin Oncol. 2021;51:1319\u201329. https:\/\/doi.org\/10.1093\/jjco\/hyab071.","journal-title":"Jpn J Clin Oncol"},{"key":"1445_CR27","unstructured":"Items and prices of drugs usable in insurance-covered healthcare. 2024. https:\/\/www.mhlw.go.jp\/topics\/2024\/04\/tp20240401-01.html."},{"key":"1445_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12029-016-9885-6","volume":"48","author":"I Tsukiyama","year":"2017","unstructured":"Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, et al. A cost-effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract cancer in Japan. J Gastrointest Cancer. 2017;48:326\u201332. https:\/\/doi.org\/10.1007\/s12029-016-9885-6.","journal-title":"J Gastrointest Cancer"},{"key":"1445_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14737167.2016.1222907","volume":"16","author":"N Paracha","year":"2016","unstructured":"Paracha N, Thuresson P-O, Moreno SG, MacGilchrist KS. Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16:549\u201359. https:\/\/doi.org\/10.1080\/14737167.2016.1222907.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1445_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","volume":"68","author":"Y Lang","year":"2023","unstructured":"Lang Y, Chai Q, Tao W, Liao Y, Liu X, Wu B. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. Breast. 2023;68:173\u201380. https:\/\/doi.org\/10.1016\/j.breast.2023.02.003.","journal-title":"Breast"},{"key":"1445_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. https:\/\/doi.org\/10.1186\/1477-7525-6-84.","journal-title":"Health Qual Life Outcomes"},{"key":"1445_CR32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","volume":"16","author":"LS Matza","year":"2015","unstructured":"Matza LS, Sapra SJ, Dillon JF, Kalsekar A, Davies EW, Devine MK, et al. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ. 2015;16:1005\u201318. https:\/\/doi.org\/10.1007\/s10198-014-0649-6.","journal-title":"Eur J Health Econ"},{"key":"1445_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/JOP.2011.000502","volume":"8","author":"EA Handorf","year":"2012","unstructured":"Handorf EA, McElligott S, Vachani A, Langer CJ, Bristol Demeter M, Armstrong K, et al. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract. 2012;8:267\u201374. https:\/\/doi.org\/10.1200\/JOP.2011.000502.","journal-title":"J Oncol Pract"},{"key":"1445_CR34","unstructured":"OECD Data. Exchange rates. https:\/\/data.oecd.org\/conve rsion\/excha nge-rates.htm. Accessed 15 Sept 2023."},{"key":"1445_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41669-023-00445-8","volume":"8","author":"A Favre-Bulle","year":"2024","unstructured":"Favre-Bulle A, Huang M, Haiderali A, Bhadhuri A. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage, triple-negative breast cancer in Switzerland. Pharmacoecon Open. 2024;8:91\u2013101. https:\/\/doi.org\/10.1007\/s41669-023-00445-8.","journal-title":"Pharmacoecon Open."},{"key":"1445_CR36","doi-asserted-by":"publisher","first-page":"756899","DOI":"10.3389\/fpubh.2021.756899","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Lang Y, Liao Y, Zhu Y. Atezolizumab plus chemotherapy vs. chemotherapy in advanced or metastatic triple-negative breast cancer: a cost-effectiveness analysis. Front Public Health. 2021;9:756899. https:\/\/doi.org\/10.3389\/fpubh.2021.756899.","journal-title":"Front Public Health"},{"key":"1445_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent R, Andr\u00e9 F, Gon\u00e7alves A, Martin M, Schmid P, Sch\u00fctz F, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024;35:630\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.001.","journal-title":"Ann Oncol"},{"key":"1445_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.004.","journal-title":"Ann Oncol"},{"key":"1445_CR39","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X.","journal-title":"Lancet"},{"key":"1445_CR40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","journal-title":"N Engl J Med"},{"key":"1445_CR41","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"1445_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.669195","volume":"11","author":"G Liu","year":"2021","unstructured":"Liu G, Kang S, Wang X, Shang F. Cost-effectiveness analysis of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status. Front Oncol. 2021;11: 669195. https:\/\/doi.org\/10.3389\/fonc.2021.669195.","journal-title":"Front Oncol"},{"key":"1445_CR43","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.21037\/atm-21-4294","volume":"9","author":"S Cheng","year":"2021","unstructured":"Cheng S, Pei R, Li J, Li B, Tang L, Yin T, et al. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives. Ann Transl Med. 2021;9:1481. https:\/\/doi.org\/10.21037\/atm-21-4294.","journal-title":"Ann Transl Med."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01445-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:02:53Z","timestamp":1749186173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01445-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01445-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"13 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors indicate no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data generated or analyzed in this study are included in the published article and references. This data may be available upon reasonable request from the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Y.C.: conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing the original draft, visualization, project administration, and funding acquisition. N.N.: writing\u2014review and editing, and supervision. T.K.: investigation. H.N.: investigation. M.H.: investigation. N.K.: writing\u2014review and editing, and supervision. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}